
Takeda, a global biopharmaceutical company, is due to launch a project, INTERCEPT, which will use biomarkers to prevent symptomatic onset …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

